Glucocorticoid
Romosozumab superior to denosumab for improving spine bone mineral density at 12 months
SAN DIEGO — Romosozumab is superior to denosumab for increasing bone mineral density in the spine at 12 months among chronic glucocorticoid users with osteoporosis at high fracture risk, according to data presented at ACR Convergence 2023.
‘Increased vigilance’ necessary when reducing glucocorticoid dose in ANCA vasculitis
SAN DIEGO — Patients with granulomatosis with polyangiitis and microscopic polyangiitis who lower their glucocorticoid dose have an increased risk for death, renal failure, progression or relapse, said a presenter at ACR Convergence 2023.
Oral nonsteroidal treatment reduces glucocorticoid dose in congenital adrenal hyperplasia
Adults with congenital adrenal hyperplasia receiving an oral corticotropin-releasing factor type 1 receptor antagonist had a greater reduction in daily glucocorticoid dose at 24 weeks than placebo, according to top-line phase 3 trial data.
Low-dose glucocorticoids for rheumatoid arthritis lead to small weight gain
When taken over 2 years for rheumatoid arthritis, low-dose glucocorticoids were associated with slight weight gain, but they did not significantly affect BP, according to research published in Annals of Internal Medicine.
‘Lipid paradox’ may obscure cardiovascular risk in patients with inflammatory disease
AUSTIN, Texas — Providers should carefully consider the “lipid paradox” when monitoring cardiovascular risks in patients with rheumatic inflammatory diseases, noted a presenter at the 2023 Rheumatology Nurses Society annual conference.
Adults hospitalized with COVID-19 have lower thyroglobulin levels with glucocorticoid use
Thyroglobulin levels differed by glucocorticoid use, but not by thyroid function, among a cohort of adults hospitalized for COVID-19, according to findings published in Frontiers in Endocrinology.
Addressing glucocorticoid withdrawal syndrome in treatment of Cushing’s syndrome
To achieve optimal outcomes in Cushing’s syndrome, both clinicians and patients need to be prepared for the type and duration of symptoms that patients may experience during treatment and recovery.
Central nervous system vasculitis treatment strategies still lack strong data
Current treatment strategies for patients with central nervous system vasculitis are not based on high-grade scientific evidence but rather expert opinion, according to a speaker at the Biologic Therapies Summit.
Patients with ANCA-associated vasculitis remain ‘soaked in steroids’ despite new therapies
DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for patients with ANCA-associated vasculitis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Top in rheumatology: Tocilizumab for giant cell arteritis; glucocorticoids for MIS-C
The European Alliance of Associations for Rheumatology issued updated guidance recommending weekly tocilizumab, along with glucocorticoids that should eventually be tapered, for patients with new, relapsing giant cell arteritis.